Midtown Partners initiates coverage on Marathon Patent Group with a Strong Buy rating and a price target of $16.73. Analysts Alec Jaslow and William Relyea believe the company has a compelling patent monetization strategy, strong foothold within the industry, and a favorable long-term outlook; which should provide upside to the share price.

Midtown Partners initiates coverage of LifeVantage Corp with a Buy rating with a price target of $1.43. Analysts Alec Jaslow and William Relyea believe the company has a compelling valuation, easier comparisons and new products that should provide upside to the share price.

Midtown Partners initiates coverage of Medifast, Inc. with a Neutral rating. Analysts Alec Jaslow and William Relyea believe the company will continue to face industry headwinds and the asset intensive nature of the company makes it less attractive than competitors that sell directly to consumers with less infrastructure.

Midtown Partners initiates coverage of CalAmp with a Strong Buy rating. Analyst Michael Rindos is optimistic about the firm’s potential to post significant revenue and cash flow gains based on the take up of its Wireless Matrix MRM solutions and shipments of subscriber equipment to other M2M customers like Catepillar.